Effects of 2-Alkylamino-Substituted Dihydropyridines on Rabbit Jejunum

Farzin Hadizadeh, Bibi Fatemeh Anaraki-Firooz, Syed Intasar Husain Taqvi

*Corresponding author: F. Hadizadeh, Department of Medicinal Chemistry, Faculty of Pharmacy, Mashhad University of Medical Sciences, P.O.Box 91775-1365, Mashhad, Iran. Fax: (+)98-511-8823251. E-mail: f-hadyzadeh@mums.ac.ir

Abstract

In order to investigate the effects of dimethylamino substituent at position 2 of the dihydropyridine nucleus on its activity, dialkyl 1,4-dihydro-2-[2-(dimethylamino) ethyl]-6-methyl-4-(1-benzyl-2-alkylthio-5-imidazolyl)-3,5-pyridinedicarboxylates (6a-f) were synthesized. The synthesis was started from dialkyl 1,4-dihydro-2,6-dimethyl-4-(1-benzyl-2-alkylthio-5-imidazolyl)-3,5-pyridinedicarboxylates (5a-f) which their synthesis and effects as calcium channel antagonist on guinea-pig ileum has been reported previously. Rabbit jejunum was used to determine the relaxant or antagonistic activity of the synthesized compounds. Some of the compounds (6c-e) inhibited the spontaneous contractile activity of jejunum, dose-dependently and completely, while high-K⁺ contracted tissues were relaxed partially.

Keywords: 2-Dimethylamino-substituted dihydropyridines; Rabbit jejunum; Calcium channel.

Received: July 2004; Accepted: October 2004

1. Introduction

Structurally diverse groups of compounds are known to be effective as calcium antagonists. The most potent known class of antagonists are 1,4-dihydropyridines, which include the widely used nifedipine. This class of compounds has been the subject of many structure-activity relationship studies [1]. In this study, we also synthesized several 2-alkylamino-substituted dihydropyridines, and investigated their calcium channel blocking activities. Starting from dialkyl 1,4-dihydro-2,6-dimethyl-4-(1-benzyl-2-alkylthio-5-imidazolyl)-3,5-pyridinedicarboxylates (5), whose synthesis and effects as calcium channel antagonist on guinea-pig ileum has been reported, previously [2], dialkyl 1,4-dihydro-2-[2-(dimethylamino)
ethyl]-6-methyl-4-(1-benzyl-2-alkylthio-5-imidazolyl)-3,5-pyridinedicarboxylates (6) were synthesized as illustrated in Scheme 1.

Rabbit jejunum was used to determine the relaxant or antagonistic activity of the synthesized compounds (6c-e). This test model, particularly allows to examine the relaxant, spasmolytic, or antagonistic activities of unknown compounds, directly without the use of an agonist [3]. We report here that the synthesized compounds inhibited the spontaneous contractile activity dose-dependently and completely, while high-K+ contracted tissues were relaxed partially.

2. Materials and methods

2.1. Chemistry

Melting points were determined using the capillary apparatus with a system of Gallenkamp. 1H-NMR spectra were run on a Bruker AC-80 spectrometer. Infrared spectra were recorded on a FT-IR Perkin-Elmer Paragon 1000 spectrophotometer. Compounds 2 to 5 were synthesized as described previously [2]. The developed procedure [4] is exemplified with the obtaining of 1,4-dihydro-2-methyl-6-[2-(dimethylamino)ethyl]-6-methyl-4-(1-benzyl-2-alkylthio-5-imidazolyl)-3,5-pyridinedicarboxylate dimethyl ester (6b).

2.2. Synthesis of 1,4-dihydro-2-methyl-6-[2-(dimethylamino)ethyl]-4-(1-benzyl-2-ethylthio-5-imidazolyl)-3,5-pyridinedicarboxylate dimethyl ester (6b)

A solution of 5b (1.2g, 2.72 mmole), dimethylamine hydrochloride (0.33 g; 4 mmol), paraformaldehyde (0.12 g, 4 mmol) and 0.05 ml of concentrated hydrochloric acid in ethanol (5 ml), while protected from
light, was heated at reflux for 10 h. The solvent was then evaporated and the residue was partitioned between hydrochloric acid (2 M; 30 ml) and ethyl acetate (15 ml). The aqueous phase was separated, basified with aqueous ammonia, and extracted into diethyl ether (3x30 ml). The extract was dried and the residue was chromatographed to give 0.4 g (30%) of 1,4-dihydro-2-methyl-6-[2-(dimethylamino)ethyl]-4-(1-benzyl-2-ethylthio-5-imidazolyl)-3,5-pyridinedicarboxylate dimethyl ester (6b) as a brown oil. IR (KBr): 1704, 1690 cm\(^{-1}\) (C=O); \(^1\)H-NMR (CDCl\(_3\)): 7.65-6.92 (m, 7H, arom, H-C\(_4\) imidazole, NH), 5.59 (s, 2H, CH\(_2\)N), 5.3 (s, 1H, H-C\(_4\) dihydropyridine), 3.6 (s, 6H, CH\(_3\)O), 3.15-2.68 (m, 6H, CH\(_2\)), 2.5 (s, 6H, NCH\(_3\)), 2.34 (s, 3H, CH\(_3\)), 1.34 (t, 3H, CH\(_3\)).

2.3. Evaluation of pharmacological activity

Male adult, healthy rabbits, ranging from 1500-150 grams, were purchased from the animal house of Mashhad University of Medical Sciences. Animals were fasted for 12 h but had free access to water before the experiments. After cervical dislocation, jejunum was isolated, the adjacent tissues were removed, and 2-3 cm long pieces were cut. Each piece was hung diagonally in a 10 ml organ bath filled with the Tyrode’s solution (composition in mM: KCl 2.7, NaCl 136.9, MgCl\(_2\) 1.1, NaHCO\(_3\) 0.4, CaCl\(_2\) 108, Glucose 5.6) and was aerated with carbogen (95% O\(_2\) and 5% CO\(_2\)) at 37 °C. The contractions were recorded with a model 7 Grass polygraph. A preload of 1.0 g was applied to each tissue. After stabilizing the tissue with 3x10\(^{-7}\) M norepinephrine, the test compounds were added in a cumulative dose-fashion. All of the compounds were dissolved in 10% DMSO and their effect on the spontaneous activity of the rabbit jejunum was determined. The experiment was repeated five times for each compound.

In a second set of experiments, calcium channel blocking activity of the compounds was studied. Eighty mM KCl was used to induce a sustained contraction. At plateau, the compounds were added in the cumulative dose-fashion. The experiments were repeated at least three times for each compound. The Prism pad was used to present the data in graphical form; the same software also calculated IC\(_{50}\) values. Student t-test was employed and the level of significance was taken at p 0.05.

3. Results and discussion

The effects of compounds 6c, 6d, and 6e in rabbit jejunum are presented in Fig1. The compound 6d and 6e showed a dose-dependent inhibition of jejunum movement, while compound 6c sharply inhibited the movements after the third dose, and then followed a dose-dependent pattern. The results presented in Table 1 shows the IC\(_{50}\) values of the test compounds, comparatively. Compound 1 is more potent in this tissue.

![Figure 1](www.SID.ir)
The dose-dependent inhibition of spontaneous contractile activity by a test compound is a characteristic of a calcium channel antagonist [5]. To determine the calcium channel antagonistic activity of the synthesized compounds, high-K⁺ was used to induce sustained contraction in the tissues. A high-K⁺ is known to cause the contraction in the smooth muscles due to entry of Ca⁺⁺ into the cells through the voltage-dependent calcium channels (VDCs) [6, 7]. The cytoplasmic calcium [Ca⁺⁺]ᵢ is responsible for activating the contractile element in the smooth muscle preparations [8]. Compounds which inhibit a high-K⁺ induced contraction is thought to be a calcium channel antagonist [9].

As shown in Figure 1, compounds 6c and 6d did not relaxed the pre-contracted tissue significantly, while compound 6e significantly relaxed the jejunum which suggest that it has partial calcium channel blocking activity.

Acknowledgement

The work was partially supported by a grant from the Research Council of Medical Sciences, Mashhad University of Medical Sciences.

References


